Premium
Lecture Abstracts
Author(s) -
Perlmutter is Executive Vice President for Research and Development at Amgen,
Inc.,
the world's largest biotechnology company. A graduate of Reed College Portland,
Oregon,
Perlmutter received his M.D. and Ph.D. degrees from Washington University in . Thereafter he …,
and in became Professor and Chairman of the Department of Immunology there. During this period,
Perlmutter focused his scientific efforts on the elucidation of signaling pathways governing …,
where,
as Executive Vice President,
Worldwide Basic and Preclinical Research,
he helped to craft strategies that led to the introduction of new therapies for serious infections …,
as well as vaccines to prevent cervical cancer and shingles. He left Merck in to lead the …,
Inc. Under his direction,
Amgen has successfully re-focused its discovery efforts on the amelioration of grievous illness,
increasing its product portfolio by five-fold. Dr. Perlmutter is also a director of Stem Cells,
a Trustee of Reed College,
and Chairman of the Board of Directors of the Institute for Systems Biology,
a not-for-profit research institute based in Seattle,
Washington. He was previously President of the American Association of Immunologists,
and is a Fellow of the American Academy of Arts and Sciences.
Publication year - 2009
Publication title -
peptide science
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.556
H-Index - 125
eISSN - 1097-0282
pISSN - 0006-3525
DOI - 10.1002/bip.21222
Subject(s) - chemistry
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom